Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

CONCLUSIONS: In this randomized phase II trial, single-agent metronomic oral vinorelbine was effective and well tolerated as first-line chemotherapy for patients with HR-positive/HER2-negative ABC. Formal comparisons are not done in this phase II study and one can simply observe that confidence intervals of all endpoints overlap. When deciding for a chemotherapy after failure of endocrine therapy and CDK 4/6 inhibitors, oral vinorelbine might be an option to be given with either schedule.CLINICAL TRIAL REGISTRATION NUMBER: EudraCT 2014-003860-19.PMID:38377732 | DOI:10.1016/j.breast.2024.103681

Source: Breast - February 20, 2024 Category: Cancer & Oncology Authors: Gilles Freyer Noelia Martinez-Ja ñez Bo żena Kukielka-Budny Malgorzata Ulanska Hugues Bourgeois Montserrat Mu ñoz Serafin Morales Juan Bayo Calero Laura Cortesi Tam ás Pintér Mark éta Palácová Nelli Cherciu Edgar Petru Johannes Ettl C écilia de A Source Type: research